Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | TMPRSS4 | Q9NRS4 | 5/20 | 0.50 |
| ▸ | CTSS | P25774 | 3/20 | 0.50 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.50 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.48 |
| ▸ | CTSK | P43235 | 2/20 | 0.48 |
| ▸ | F2R | P25116 | 1/20 | 0.47 |
| ▸ | PTPRC | P08575 | 1/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.46 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | PTGES | O14684 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2851356 | 0.82 | LMNA (0.57) | NPC1RAB9ATMPRSS4CTSSKCNK3 | |
| SCHEMBL31423384 | 0.77 | RAB9A (0.60) | NPC1RAB9A | |
| SCHEMBL31423361 | 0.75 | NPC1 (0.56) | NPC1RAB9APTGS1PTGES | |
| SCHEMBL31423393 | 0.75 | ESR1 (0.60) | NPC1RAB9ACTSSKCNK3KCNK9 | |
| SCHEMBL2849166 | 0.75 | BTK (0.45) | RAB9AKCNK3KCNK9PTGS1BRAF | |
| SCHEMBL31423382 | 0.74 | NPC1 (0.55) | NPC1RAB9ACTSSKCNK3KCNK9 | |
| SCHEMBL31423363 | 0.74 | MEN1 (0.64) | NPC1RAB9ATMPRSS4CTSSKCNK3 | |
| SCHEMBL2680915 | 0.74 | KDR (0.76) | TMPRSS4 | |
| SCHEMBL7984064 | 0.74 | CTSS (0.63) | CTSSCTSKP2RX7 | |
| SCHEMBL330225 | 0.74 | TMPRSS4 (0.79) | NPC1RAB9ATMPRSS4P2RX1SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2184285-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-11-04 | — | — | EP | disclosed |
| US-8344135-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-01 | — | — | US | disclosed |
| US-20100249119-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2184285-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249119-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BRAF, NRAS, RAF1 | NPC1 3266/4885RAB9A 383/4885TMPRSS4 3406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.